Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials
- 9 May 2009
- Vol. 27 (31) , 4079-4089
- https://doi.org/10.1016/j.vaccine.2009.04.059
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly AdultsPLOS ONE, 2009
- Safety, Humoral and Cell Mediated Immune Responses to Two Formulations of an Inactivated, Split-Virion Influenza A/H5N1 Vaccine in ChildrenPLOS ONE, 2008
- Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and childrenVaccine, 2008
- Antigenically Distinct MF59-Adjuvanted Vaccine to Boost Immunity to H5N1New England Journal of Medicine, 2008
- Report of the 4th meeting on the “Evaluation of pandemic influenza prototype vaccines in clinical trials”: World Health Organization, Geneva, Switzerland, 14–15 February 2008Vaccine, 2008
- Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adultsVaccine, 2008
- Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in AdultsThe Journal of Infectious Diseases, 2008
- Cross‐neutralisation of antibodies elicited by an inactivated split‐virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strainsInfluenza and Other Respiratory Viruses, 2007
- Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trialThe Lancet, 2007
- Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trialThe Lancet, 2006